Rifampicin and hepatic toxicity
Purohit, S.D.; Gupta, P.R.; Sharma, T.N.; Gupta, D.N. and Chawla, M.R. (1983) Rifampicin and hepatic toxicity. Indian Journal of Tuberculosis, 30 (3). pp. 107-109.
Full text available as:
110 patients of sputum smear positive pulmonary tuberculosis were randomly put on two antituberculous drug regimens and hepatotoxicity of the regimens was studied during the therapy. Four out of 57 patients (7%) on rifampicin containing drug regimen developed transient hepatitis as compared to none out of 53 (0%) patients on non-rifampicin drug regimen. Abnormal ALT levels were observed in 40.3% of patients on rifampicin containing drug regimen as compared to 7.5% of patients on non-rifampicin drug regimen. Clinical symptoms related to hepatitis preceded deranged enzyme levels in 3 patients and followed it in 1 patient on rifampicin therapy Clinical symptoms of hepatitis appear to be a useful index of hepatotoxicity of rifampicin and routine biochemical monitoring may not be essential. However, symptoms suggestive of” hepatitis are not specific and should be followed by enzyme estimations.
Archive Staff Only: edit this record